John Fesko, the President and Chief Business Officer of Natera, Inc. (NASDAQ:NTRA), recently sold shares of the company’s common stock, according to a regulatory filing submitted on December 26, 2024. The company, currently valued at $21.1 billion, has seen its stock surge over 160% in the past year, according to InvestingPro data. The sale, executed on December 23, amounted to a total of $106,773.
The transactions involved selling 669 shares at prices ranging from $157.9504 to $159.6041 per share. These sales were conducted to meet tax withholding obligations related to the vesting of Restricted Stock Units (RSUs), as detailed in the filing. Following these transactions, Fesko retains direct ownership of 114,142 shares of Natera’s common stock. InvestingPro analysis indicates the company maintains a strong financial position with a current ratio of 4.39, suggesting ample liquidity to meet short-term obligations.
The RSUs, initially granted on October 22, 2021, vested upon achieving specific business performance criteria, leading to the recent sale to cover the associated tax liabilities. According to InvestingPro, which offers 12 additional investment tips for Natera, the company maintains a GOOD overall financial health score despite showing high price volatility.
In other recent news, genetic testing company Natera Inc (NASDAQ:). reported a significant increase in Q3 revenue, reaching a record $439.8 million, a 64% increase year-over-year. The company conducted 137,000 oncology tests, marking a 54% increase from the previous year. Additionally, Natera’s gross margins reached a record high of 62%, causing a revision of its full-year revenue guidance to between $1.61 billion and $1.64 billion.
In response to these developments, TD Cowen, Baird, and Jefferies maintained favorable ratings on Natera’s stock, with TD Cowen raising the price target from $175 to $195. Despite a setback in a false advertising lawsuit against Guardant Health (NASDAQ:), Natera plans to request the court to overturn the ruling.
Natera also expanded its patent infringement litigation against NeoGenomics (NASDAQ:), involving the RaDaR assay. An additional patent was included in the ongoing lawsuit, following a recent court decision. Furthermore, an agreement with Dr. Rabinowitz, the Executive Chairman, was amended to continue his role under certain conditions. These recent developments provide investors with a glimpse into Natera’s current status.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
